Alvacan XO is a future-oriented oncolytic immunotherapy that can be used either alone or in combination with surgery, other cancer treatments, and other non-overlapping immunotherapy.

Recombinant DNA / RNA technology and findings from cancer stem cell research will make this vaccine more effective and adapted to the cancer diagnosis. Different modules can be assembled in several versions of XO. High efficacy and few side effects are expected.

Alvacan XO is a so-called “off-the-shelf product” that is well suited for mass production and also has great potential for human immunotherapy.